Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Colitis Ulcerative Clear all
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

NCT07113522
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Interventions
MT-501, MT-201
Drug
Lead sponsor
Mirador Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional

A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease

NCT05651542
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Comprehensive Self-Management Intervention, Control
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Not yet recruiting Phase 1 Interventional

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

NCT05852587
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions
Xylitol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 2 Interventional

Study of Novel Therapeutics for Acute Remedy of Colitis

NCT06420492
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Interventions
BRS201
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Withdrawn Early Phase 1 Interventional

Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.

NCT03309865
View directory record Official record
Conditions
Ulcerative Colitis, Dietary Modification
Interventions
semi-vegetarian diet, Vedolizumab Injection
Dietary Supplement · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05499130
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
TEV-48574, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
36
States / cities
Sun City, Arizona • San Diego, California • Kissimmee, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Improving Medication Adherence in Pediatric Inflammatory Bowel Disease

NCT01536509
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Disease
Interventions
Telehealth Behavioral Treatment (TBT), Education Only (EO)
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
San Francisco, California • Hartford, Connecticut • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 10, 2026, 4:41 PM EDT
Withdrawn Phase 2 Interventional

Lactobacillus GG in Pediatric Ulcerative Colitis (UC)

NCT00895336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lactobacillus GG
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 2 Interventional

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LY4268989, Mirikizumab, LY4268989 Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

NCT02958865
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
60
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Impact on Intestinal Sulfate Metabolism

NCT05333900
View directory record Official record
Conditions
Healthy Nutrition
Interventions
Plant-Based Diet then animal-based diet, Animal-based diet then plant-based diet
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting Not applicable Interventional

Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis

NCT05213234
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Chronotherapy
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational Results available

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

NCT03801928
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Inflectra
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
San Diego, California • Hamden, Connecticut • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 10, 2026, 4:41 PM EDT
Completed No phase listed Observational

Fecal Calprotectin Collection Protocol

NCT03143517
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease, Indeterminate Colitis, Chronic Diarrhea, Celiac Disease, Diverticulitis, Abdominal Pain, Distension, Weight Loss, Food Intolerance, Constipation
Interventions
Stool collection
Diagnostic Test
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
4 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Dothan, Alabama • Little Rock, Arkansas • Mission Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

GB004 in Adult Subjects With Active Ulcerative Colitis

NCT03860896
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GB004, Placebo
Drug
Lead sponsor
GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Monroe, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional

An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy

NCT00467922
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Rectal Cancer, Colon Cancer, Colon Polyps, Rectal Polyps, Diverticulitis
Interventions
Hextend, Lactated Ringers
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 20, 2009 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis

NCT00718094
View directory record Official record
Conditions
Mild to Moderately Active Ulcerative Colitis
Interventions
Polyphenon E®, Placebo Oral Tablet
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2Phase 3 Interventional

Research Study in Patients With Severe Ulcerative Colitis

NCT00032305
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

NCT03482635
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Hamden, Connecticut • Miami, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

NCT00503243
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Delayed and extended release mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 4 Interventional Results available

An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease

NCT02566889
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
6 Years to 16 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT06260163
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab Subcutaneous, Guselkumab Intravenous
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Oakland, California • Indianapolis, Indiana • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

GI Permeability Change in Response to Aquamin®

NCT04855799
View directory record Official record
Conditions
Ulcerative Colitis, Healthy, Irritable Bowel Syndrome With Diarrhea
Interventions
Aquamin
Drug
Lead sponsor
James Varani
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 3 Interventional Results available

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

NCT02118584
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
57
States / cities
Birmingham, Alabama • La Jolla, California • Orange, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 10, 2026, 4:41 PM EDT